Keros Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Keros Therapeutics, Inc. (KROS) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of -$52.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-04
- Keros Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was -$52.00M, a 202.77% decline from fiscal 2024.
- Keros Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $50.60M, a 30.75% increase from fiscal 2023.
- Keros Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $38.70M, a 53.57% increase from fiscal 2022.
- Keros Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $25.20M, a 44.00% increase from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$52.00M 10-K · filed 2026-03-04 | |
| 2024-12-31 | $50.60M 10-K · filed 2026-03-04 | -$50.60M 10-K · filed 2025-02-26 |
| 2023-12-31 | $38.70M 10-K · filed 2025-02-26 | |
| 2022-12-31 | $25.20M 10-K · filed 2024-02-28 | |
| 2021-12-31 | $17.50M 10-K · filed 2024-02-28 | |
| 2020-12-31 | $12.00M 10-K · filed 2022-03-09 | |
| 2019-12-31 | $2.60M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |